trial · primary record
Alisertib
Small Cell Lung Cancer ( SCLC )
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2028-09-30 |
| Primary endpoint | Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) |
| Registry ID | NCT07465757 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:54.673Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07465757
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.